Scipio News

30
November
2021

Scipio bioscience President Prof. Stuart Edelstein presents the single-cell hydrogel technology

At the Next Gen Omics UK conference on November 5th, SCIPIO BIOSCIENCE President and Chief Scientific Officer Prof. Stuart Edelstein presented the technology and the validation data behind the upcoming single-cell RNA-seq benchtop kit. A recording of the talk is now freely available online.
3
November
2021

Scipio bioscience at Next Gen Omics 2021!

Scipio bioscience will be present in-person this week (Nov 4-5) at Next Gen Omics UK, one of the largest genomics events in Europe! President and CSO Prof. Stuart Edelstein will be giving a talk about the technology behind Scipio bioscience's scRNA-seq solution.
5
February
2021

The Benchtop Single-Cell Letter has launched!

The first issue of the Benchtop Single-Cell Letter is out! Each issue will focus on a theme around single-cell sciences, and you can receive the bimonthly publication simply by signing up on our website!
28
January
2021

Welcome to our two new directors!

Scipio continues its expansion in 2021 with the hiring of a VP Chief Manufacturing Officer and a Director of Bioinformatics! Pierre Chaumat and Barbara André have joined the team this January to take part in the development of the Scipio kit.
3
November
2020

The new Scipio website is here!

Scipio has been riding its initial success and significantly expanded since its inception, and a new website was required to reflect such progress! You can now find more details about the Scipio technology and the team members, but its most important feature is the launch of the new Benchtop Single-Cell blog which will focus on, well, single-cell science.
25
February
2020

Scipio bioscience announces its Series A fund raising

A total of €6.0m has been obtained from an international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck. The initial shareholders Seventure Partners' Quadrivum I (Paris, France) and High-Tech Gründerfonds (Bonn, Germany) participated in the capital increase, alongside additional investors Financière Arbevel (Paris, France) and Investiere Venture Capital (Zürich, Switzerland).